Stock 0NWK VALERIO THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

News Valerio Therapeutics London S.E.

Equities

0NWK

FR0010095596

Delayed London S.E.
Other stock markets
 06:18:08 2020-11-30 am EST 		5-day change 1st Jan Change
0.7551 EUR -0.52% Intraday chart for Valerio Therapeutics +514.40% +335.72%
May. 22 Valerio Therapeutics S.A. Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial CI
Apr. 30 Valerio Therapeutics Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Valerio Therapeutics: Report on the Combined General Meeting of June 4, 2024
BU
Valerio Therapeutics : Reports Full Year 2023 Financial Results and Provides Clinical Development Updates
PU
Valerio Therapeutics Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial
BU
Valerio Therapeutics S.A. Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial
CI
Valerio Therapeutics : Publication of the 2023 Annual Report
PU
Valerio Therapeutics : Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via Systemic Administration in the United States
PU
Valerio Therapeutics : Onxeo Announces the Transfer of the Listing of its Shares to Euronext Growth Paris on December 15, 2020
PU
Valerio Therapeutics : Annual financial and audit reports / Terms of availability of the annual financial report
PU
Valerio Therapeutics Reports Full Year 2023 Financial Results and Provides Clinical Development Updates
BU
Valerio Therapeutics Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Valerio Therapeutics : Reports Full Year 2023 Financial Results and Provides Clinical Development Updates
PU
Valerio Therapeutics : Publication of the 2023 Annual Report
PU
Valerio Therapeutics Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Onxeo : changes its name and becomes Valerio Therapeutics following approval by the Annual General Meeting of June 6, 2023
PU
Onxeo SA has Changed its Name to Valerio Therapeutics
CI
Biophytis' Finance Chief Resigns; Onxeo Exec Named Successor
MT
Onxeo SA Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Onxeo: Publication of the 2022 Annual Financial Report
BU
Onxeo Reports Full Year 2022 Financial Results and Provides Clinical Development Updates
BU
Onxeo will publish its full-year results on April 24, 2023
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALVIO Stock
  4. 0NWK Stock
  5. News Valerio Therapeutics